Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.72 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.70 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.67 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31546799 | 1.00 | CRBN (0.72) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL14506394 | 0.91 | CRBN (0.72) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL23226142 | 0.89 | CRBN (0.70) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL29547357 | 0.88 | IKZF2 (0.74) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL25571538 | 0.88 | IKZF2 (0.74) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL19503550 | 0.88 | IKZF2 (0.74) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL25628768 | 0.87 | CRBN (0.74) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL23980626 | 0.86 | CRBN (0.66) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL21982892 | 0.85 | CRBN (0.78) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL21982827 | 0.85 | CRBN (0.78) | CRBNIKZF2CSNK1A1GSPT1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2022066835-A1 | SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | CRBN 764/4885IKZF2 4089/4885CSNK1A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.